Skip to content

We are currently experiencing some technical difficulties which may result in you experiencing longer than usual wait times on our telephone and chat channels. We apologise for the inconvenience but ask you to hold once in the queue as we will get to your call and resolve your query.

 

Most Favoured Nation (MFN) & International Reference Pricing (IRP) for Orphan Medicines

Access to orphan medicines is becoming increasingly influenced by global pricing policy. As Most Favoured Nation (MFN) pricing and International Reference Pricing (IRP) become more closely interconnected, pharmaceutical companies are rethinking how they approach European launches, pricing strategies and patient access.

This whitepaper shares key insights from a pre-conference workshop at the World Orphan Drug Congress (WODC) USA, featuring Andrew Cummins (Sciensus) and Dee Chaudhary (Clarivate). Combining expert perspectives, live audience polling and interactive scenario discussions, it explores how MFN and IRP are reshaping the future of orphan drug commercialisation.

Download to discover:

  • How MFN is reshaping global pricing and launch strategy for orphan medicines
  • Why European pricing decisions now have wider commercial implications
  • The latest industry insights from live polling with rare disease leaders
  • How organisations are adapting launch sequencing and early access strategies
  • Practical considerations for managing pricing risk while protecting patient access

Download your free copy to explore the data and explore how MFN and IRP are transforming the future of European access and global launch strategy.

Sciensus

About Sciensus

Sciensus is the UK’s leading provider of complex clinical care at home. For over 30 years, we have partnered with the NHS to deliver specialist medicines, clinical nursing and patient support to people living with cancer, rare diseases and complex long-term conditions – supporting more than 300,000 patients a year across 180+ NHS trusts.

Beyond the UK, Sciensus helps pharmaceutical and biotech companies reach patients across Europe, managing the regulatory, logistics and patient support complexity of launching medicines in multiple markets.

Learn more